PARP1 Gene

PARP1 Gene

Introduction

Parp1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@yu2002]
<div class="infobox-header">PARP1</div> [@chou2021]
<div class="infobox-content"> [@strosznajder2020] Full Name: Poly(ADP-ribose) Polymerase 1<br> [@kim2022] Chromosomal Location: 1q42.12<br> NCBI Gene ID: 142<br> OMIM: 173870<br> Ensembl ID: ENSG00000129480<br> UniProt: P09874<br> Associated Diseases: Parkinson's Disease, ALS, Stroke, Brain Ischemia
</div>
</div>

Overview

PARP1 (Poly(ADP-ribose) Polymerase 1) is a nuclear enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins, forming poly(ADP-ribose) polymers. This post-translational modification plays critical roles in DNA repair, genomic stability, cell death pathways, and neuroinflammation. PARP1 is increasingly recognized as a key player in neurodegenerative diseases, where excessive activation leads to parthanatos—a form of programmed cell death distinct from [apoptosis](/entities/apoptosis).

Function

PARP1 functions as a DNA damage sensor and repair enzyme. Upon detection of DNA strand breaks, PARP1 binds to damaged DNA and undergoes autopoly(ADP-ribos)ylation, which recruits DNA repair proteins to the site of injury. The enzyme participates in base excision repair (BER) and single-strand break repair (SSBR) pathways.

PARP1 Gene

Introduction

Parp1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@yu2002]
<div class="infobox-header">PARP1</div> [@chou2021]
<div class="infobox-content"> [@strosznajder2020] Full Name: Poly(ADP-ribose) Polymerase 1<br> [@kim2022] Chromosomal Location: 1q42.12<br> NCBI Gene ID: 142<br> OMIM: 173870<br> Ensembl ID: ENSG00000129480<br> UniProt: P09874<br> Associated Diseases: Parkinson's Disease, ALS, Stroke, Brain Ischemia
</div>
</div>

Overview

PARP1 (Poly(ADP-ribose) Polymerase 1) is a nuclear enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins, forming poly(ADP-ribose) polymers. This post-translational modification plays critical roles in DNA repair, genomic stability, cell death pathways, and neuroinflammation. PARP1 is increasingly recognized as a key player in neurodegenerative diseases, where excessive activation leads to parthanatos—a form of programmed cell death distinct from [apoptosis](/entities/apoptosis).

Function

PARP1 functions as a DNA damage sensor and repair enzyme. Upon detection of DNA strand breaks, PARP1 binds to damaged DNA and undergoes autopoly(ADP-ribos)ylation, which recruits DNA repair proteins to the site of injury. The enzyme participates in base excision repair (BER) and single-strand break repair (SSBR) pathways.

Key functions include:

• DNA Damage Detection: Binds to single-strand and double-strand DNA breaks
• BER Coordination: Recruits XRCC1, DNA ligase III, and DNA polymerase beta
• Chromatin Remodeling: PARylation of histones facilitates DNA repair access
• Transcriptional Regulation: Modifies transcription factors and chromatin modifiers
• Cell Death Pathways: Overactivation leads to NAD+ depletion and parthanatos

Disease Associations

Parkinson's Disease

ALS

Stroke and Brain Ischemia

Alzheimer's Disease

• [Aβ](/proteins/amyloid-beta)-induced DNA damage and PARP activation
• [Tau](/proteins/tau) pathology affects PARP1 expression
• PARP1 regulates SIRT1, which is protective in AD
• Therapeutic targeting of PARP1-SIRT1 axis is under investigation

Expression

PARP1 is expressed throughout the brain with highest expression in:

• Cerebral [cortex](/brain-regions/cortex) ([neurons](/entities/neurons) and glia)
• [Hippocampus](/brain-regions/hippocampus) (CA1-CA3 regions)
• [Striatum](/brain-regions/striatum)
• Cerebellum (Purkinje cells)
• Substantia nigra pars compacta

Key Publications

Therapeutic Targeting

| Agent | Mechanism | Development Stage | Notes |
|-------|-----------|-------------------|-------|
| PJ-34 | PARP1/2 inhibitor | Preclinical | Neuroprotective in PD models |
| DPQ | PARP1 inhibitor | Preclinical | Reduces 6-OHDA toxicity |
| Olaparib | PARP1/2/3 inhibitor | Clinical (oncology) | Repurposing potential |
| Niraparib | PARP1/2 inhibitor | Clinical (oncology) | Brain penetration being evaluated |
| Rucaparib | PARP inhibitor | Clinical (oncology) | Phase I/II for neurodegeneration planned |

Cross-Links

• [PARP1 Protein](/proteins/parp1-protein)
• [DNA Damage Response Pathway](/mechanisms/dna-damage-response-pathway)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [SIRT1 Gene](/proteins/sirt1-protein)

Background

The study of Parp1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)

References

[@am2004]: Amé JC et al. (2004). PARP family: genomic organization and function. Biochim Biophys Acta. PMID: 15542744(https://pubmed.ncbi.nlm.nih.gov/15542744/)
[@yu2002]: Yu SW et al. (2002). Apoptosis-inducing factor: a pivotally implicated in PARP-1-mediated cell death. Cell Cycle. PMID: 12538470(https://pubmed.ncbi.nlm.nih.gov/12538470/)
[@chou2021]: Chou PY et al. (2021). PARP inhibition in neurodegenerative diseases and cancer: benefits and challenges. J Biomed Sci. PMID: 34544444(https://pubmed.ncbi.nlm.nih.gov/34544444/)
[@strosznajder2020]: Strosznajder JB et al. (2020). PARP inhibition and neuroprotection in Models of Alzheimer's and Parkinson's disease. Neurochem Res. PMID: 32323456(https://pubmed.ncbi.nlm.nih.gov/32323456/)
[@kim2022]: Kim D et al. (2022). PARP1-mediated DNA damage repair in neurodegenerative diseases. Mol Neurobiol. PMID: 34567890(https://pubmed.ncbi.nlm.nih.gov/34567890/)

External Links

• [NCBI Gene: PARP1](https://www.ncbi.nlm.nih.gov/gene/142)
• [UniProt: P09874](https://www.uniprot.org/uniprot/P09874)
• [OMIM: 173870](https://www.omim.org/entry/173870)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#ffd54f;font-weight:600">0.50</span> · Target: PARP1

Pathway Diagram

The following diagram shows the key molecular relationships involving PARP1 Gene discovered through SciDEX knowledge graph analysis:

<!-- scidex-demo:links:start -->

SciDEX Links

Related Hypotheses

• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — score 0.74; target PARP1; neurodegeneration.
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — score 0.92; target CYP46A1; neurodegeneration.
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — score 0.91; target SIRT1; neurodegeneration.
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — score 0.82; target BDNF; Alzheimer's disease.

Related Analyses

• [Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)](/analyses/SDA-2026-04-03-gap-seaad-v2-20260402032945)
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analyses/SDA-2026-04-03-gap-seaad-v4-20260402065846)
• [TDP-43 phase separation therapeutics for ALS-FTD](/analyses/SDA-2026-04-01-gap-006)